Toxicity to Tumors not to Patients
EpicentRx is developing new mechanisms of immunotherapy that act alone or in combination with other medicines to outsmart cancer with minimal toxicity across diverse patient populations and tumor types.

RECENT NEWS
July 1, 2020
June 10, 2020
May 29, 2020
EpicentRx Appoints Oncologist Tony Reid, M.D., Ph.D., as Chief Executive Officer (CEO)
March 3, 2020
December 4, 2019
November 25, 2019
November 13, 2019
November 05, 2019
June 25, 2019
May 02, 2018
EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines